Trials for dry-AMD treatment begin

Israel’s Cell Cure is commencing a Phase I/IIa study of its OpRegen treatment for geographic atrophy (GA), the severe stage of the dry form of age-related macular degeneration (dry-AMD). Cell Cure has received another NIS 6.24 million grant from Israel’s Chief Scientist.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *